Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease

X
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simufilam (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Registrational; Therapeutic Use
  • Acronyms RETHINK-1; RETHINK-ALZ
  • Sponsors Cassava Sciences
  • Most Recent Events

    • 10 May 2024 According to a Cassava Sciences media release, top-line data readout for our 52-week study (RETHINK-ALZ) is expected in year-end 2024.
    • 25 Mar 2024 According to a Cassava Sciences media release, the company announced the completion of another interim patient safety review by an Independent Data and Safety Monitoring Board (DSMB). DSMB recommended that trial continue as planned, without modification.
    • 07 Mar 2024 Baseline Characteristics of RETHINK and REFOCUS Phase 3 trials presented at the 2024 International Conference on Alzheimer's and Parkinson's Disease (AD/PD 2024).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top